United States Overactive Bladder Therapeutics Market Report 2017

October 2017 | 104 pages | ID: UC21E85CBDCPEN
QYResearch

Abstracts

In this report, the United States Overactive Bladder Therapeutics market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report splits the United States market into seven regions:

• The West
• Southwest
• The Middle Atlantic
• New England
• The South
• The Midwest
• with sales (volume), revenue (value), market share and growth rate of Overactive Bladder Therapeutics in these regions, from 2012 to 2022 (forecast).

United States Overactive Bladder Therapeutics market competition by top manufacturers/players, with Overactive Bladder Therapeutics sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including

• Actavis
• Allergan
• Astellas Pharma
• Pfizer
• Addex Pharmaceuticals Ltd
• Bayer
• Elbion
• Ipsen
• Janssen
• Kissei Pharma

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into

• Anti-Muscarinic Agent
• Beta-3-Adrenergic Receptor Agonist
• Others

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of Overactive Bladder Therapeutics for each application, including

• Medical Care
• Medical Research
• Others

If you have any special requirements, please let us know and we will offer you the report as you want.

Contents

United States Overactive Bladder Therapeutics Market Report 2017

1 OVERACTIVE BLADDER THERAPEUTICS OVERVIEW

1.1 Product Overview and Scope of Overactive Bladder Therapeutics
1.2 Classification of Overactive Bladder Therapeutics by Product Category
  1.2.1 United States Overactive Bladder Therapeutics Market Size (Sales Volume) Comparison by Type (2012-2022)
  1.2.2 United States Overactive Bladder Therapeutics Market Size (Sales Volume) Market Share by Type (Product Category) in 2016
  1.2.3 Anti-Muscarinic Agent
  1.2.4 Beta-3-Adrenergic Receptor Agonist
  1.2.5 Others
1.3 United States Overactive Bladder Therapeutics Market by Application/End Users
  1.3.1 United States Overactive Bladder Therapeutics Market Size (Consumption) and Market Share Comparison by Application (2012-2022)
  1.3.2 Medical Care
  1.3.3 Medical Research
  1.3.4 Others
1.4 United States Overactive Bladder Therapeutics Market by Region
  1.4.1 United States Overactive Bladder Therapeutics Market Size (Value) Comparison by Region (2012-2022)
  1.4.2 The West Overactive Bladder Therapeutics Status and Prospect (2012-2022)
  1.4.3 Southwest Overactive Bladder Therapeutics Status and Prospect (2012-2022)
  1.4.4 The Middle Atlantic Overactive Bladder Therapeutics Status and Prospect (2012-2022)
  1.4.5 New England Overactive Bladder Therapeutics Status and Prospect (2012-2022)
  1.4.6 The South Overactive Bladder Therapeutics Status and Prospect (2012-2022)
  1.4.7 The Midwest Overactive Bladder Therapeutics Status and Prospect (2012-2022)
1.5 United States Market Size (Value and Volume) of Overactive Bladder Therapeutics (2012-2022)
  1.5.1 United States Overactive Bladder Therapeutics Sales and Growth Rate (2012-2022)
  1.5.2 United States Overactive Bladder Therapeutics Revenue and Growth Rate (2012-2022)

2 UNITED STATES OVERACTIVE BLADDER THERAPEUTICS MARKET COMPETITION BY PLAYERS/SUPPLIERS

2.1 United States Overactive Bladder Therapeutics Sales and Market Share of Key Players/Suppliers (2012-2017)
2.2 United States Overactive Bladder Therapeutics Revenue and Share by Players/Suppliers (2012-2017)
2.3 United States Overactive Bladder Therapeutics Average Price by Players/Suppliers (2012-2017)
2.4 United States Overactive Bladder Therapeutics Market Competitive Situation and Trends
  2.4.1 United States Overactive Bladder Therapeutics Market Concentration Rate
  2.4.2 United States Overactive Bladder Therapeutics Market Share of Top 3 and Top 5 Players/Suppliers
  2.4.3 Mergers & Acquisitions, Expansion in United States Market
2.5 United States Players/Suppliers Overactive Bladder Therapeutics Manufacturing Base Distribution, Sales Area, Product Type

3 UNITED STATES OVERACTIVE BLADDER THERAPEUTICS SALES (VOLUME) AND REVENUE (VALUE) BY REGION (2012-2017)

3.1 United States Overactive Bladder Therapeutics Sales and Market Share by Region (2012-2017)
3.2 United States Overactive Bladder Therapeutics Revenue and Market Share by Region (2012-2017)
3.3 United States Overactive Bladder Therapeutics Price by Region (2012-2017)

4 UNITED STATES OVERACTIVE BLADDER THERAPEUTICS SALES (VOLUME) AND REVENUE (VALUE) BY TYPE (PRODUCT CATEGORY) (2012-2017)

4.1 United States Overactive Bladder Therapeutics Sales and Market Share by Type (Product Category) (2012-2017)
4.2 United States Overactive Bladder Therapeutics Revenue and Market Share by Type (2012-2017)
4.3 United States Overactive Bladder Therapeutics Price by Type (2012-2017)
4.4 United States Overactive Bladder Therapeutics Sales Growth Rate by Type (2012-2017)

5 UNITED STATES OVERACTIVE BLADDER THERAPEUTICS SALES (VOLUME) BY APPLICATION (2012-2017)

5.1 United States Overactive Bladder Therapeutics Sales and Market Share by Application (2012-2017)
5.2 United States Overactive Bladder Therapeutics Sales Growth Rate by Application (2012-2017)
5.3 Market Drivers and Opportunities

6 UNITED STATES OVERACTIVE BLADDER THERAPEUTICS PLAYERS/SUPPLIERS PROFILES AND SALES DATA

6.1 Actavis
  6.1.1 Company Basic Information, Manufacturing Base and Competitors
  6.1.2 Overactive Bladder Therapeutics Product Category, Application and Specification
    6.1.2.1 Product A
    6.1.2.2 Product B
  6.1.3 Actavis Overactive Bladder Therapeutics Sales, Revenue, Price and Gross Margin (2012-2017)
  6.1.4 Main Business/Business Overview
6.2 Allergan
  6.2.2 Overactive Bladder Therapeutics Product Category, Application and Specification
    6.2.2.1 Product A
    6.2.2.2 Product B
  6.2.3 Allergan Overactive Bladder Therapeutics Sales, Revenue, Price and Gross Margin (2012-2017)
  6.2.4 Main Business/Business Overview
6.3 Astellas Pharma
  6.3.2 Overactive Bladder Therapeutics Product Category, Application and Specification
    6.3.2.1 Product A
    6.3.2.2 Product B
  6.3.3 Astellas Pharma Overactive Bladder Therapeutics Sales, Revenue, Price and Gross Margin (2012-2017)
  6.3.4 Main Business/Business Overview
6.4 Pfizer
  6.4.2 Overactive Bladder Therapeutics Product Category, Application and Specification
    6.4.2.1 Product A
    6.4.2.2 Product B
  6.4.3 Pfizer Overactive Bladder Therapeutics Sales, Revenue, Price and Gross Margin (2012-2017)
  6.4.4 Main Business/Business Overview
6.5 Addex Pharmaceuticals Ltd
  6.5.2 Overactive Bladder Therapeutics Product Category, Application and Specification
    6.5.2.1 Product A
    6.5.2.2 Product B
  6.5.3 Addex Pharmaceuticals Ltd Overactive Bladder Therapeutics Sales, Revenue, Price and Gross Margin (2012-2017)
  6.5.4 Main Business/Business Overview
6.6 Bayer
  6.6.2 Overactive Bladder Therapeutics Product Category, Application and Specification
    6.6.2.1 Product A
    6.6.2.2 Product B
  6.6.3 Bayer Overactive Bladder Therapeutics Sales, Revenue, Price and Gross Margin (2012-2017)
  6.6.4 Main Business/Business Overview
6.7 Elbion
  6.7.2 Overactive Bladder Therapeutics Product Category, Application and Specification
    6.7.2.1 Product A
    6.7.2.2 Product B
  6.7.3 Elbion Overactive Bladder Therapeutics Sales, Revenue, Price and Gross Margin (2012-2017)
  6.7.4 Main Business/Business Overview
6.8 Ipsen
  6.8.2 Overactive Bladder Therapeutics Product Category, Application and Specification
    6.8.2.1 Product A
    6.8.2.2 Product B
  6.8.3 Ipsen Overactive Bladder Therapeutics Sales, Revenue, Price and Gross Margin (2012-2017)
  6.8.4 Main Business/Business Overview
6.9 Janssen
  6.9.2 Overactive Bladder Therapeutics Product Category, Application and Specification
    6.9.2.1 Product A
    6.9.2.2 Product B
  6.9.3 Janssen Overactive Bladder Therapeutics Sales, Revenue, Price and Gross Margin (2012-2017)
  6.9.4 Main Business/Business Overview
6.10 Kissei Pharma
  6.10.2 Overactive Bladder Therapeutics Product Category, Application and Specification
    6.10.2.1 Product A
    6.10.2.2 Product B
  6.10.3 Kissei Pharma Overactive Bladder Therapeutics Sales, Revenue, Price and Gross Margin (2012-2017)
  6.10.4 Main Business/Business Overview

7 OVERACTIVE BLADDER THERAPEUTICS MANUFACTURING COST ANALYSIS

7.1 Overactive Bladder Therapeutics Key Raw Materials Analysis
  7.1.1 Key Raw Materials
  7.1.2 Price Trend of Key Raw Materials
  7.1.3 Key Suppliers of Raw Materials
  7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
  7.2.1 Raw Materials
  7.2.2 Labor Cost
  7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Overactive Bladder Therapeutics

8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

8.1 Overactive Bladder Therapeutics Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Overactive Bladder Therapeutics Major Manufacturers in 2016
8.4 Downstream Buyers

9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

9.1 Marketing Channel
  9.1.1 Direct Marketing
  9.1.2 Indirect Marketing
  9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
  9.2.1 Pricing Strategy
  9.2.2 Brand Strategy
  9.2.3 Target Client
9.3 Distributors/Traders List

10 MARKET EFFECT FACTORS ANALYSIS

10.1 Technology Progress/Risk
  10.1.1 Substitutes Threat
  10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change

11 UNITED STATES OVERACTIVE BLADDER THERAPEUTICS MARKET SIZE (VALUE AND VOLUME) FORECAST (2017-2022)

11.1 United States Overactive Bladder Therapeutics Sales Volume, Revenue Forecast (2017-2022)
11.2 United States Overactive Bladder Therapeutics Sales Volume Forecast by Type (2017-2022)
11.3 United States Overactive Bladder Therapeutics Sales Volume Forecast by Application (2017-2022)
11.4 United States Overactive Bladder Therapeutics Sales Volume Forecast by Region (2017-2022)

12 RESEARCH FINDINGS AND CONCLUSION

13 APPENDIX

13.1 Methodology/Research Approach
  13.1.1 Research Programs/Design
  13.1.2 Market Size Estimation
  13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
  13.2.1 Secondary Sources
  13.2.2 Primary Sources
13.3 Disclaimer


The report requires updating with new data and is sent in 2-3 business days after order is placed.

List Of Tables

LIST OF TABLES AND FIGURES

Figure Product Picture of Overactive Bladder Therapeutics
Figure United States Overactive Bladder Therapeutics Market Size (K Units) by Type (2012-2022)
Figure United States Overactive Bladder Therapeutics Sales Volume Market Share by Type (Product Category) in 2016
Figure Anti-Muscarinic Agent Product Picture
Figure Beta-3-Adrenergic Receptor Agonist Product Picture
Figure Others Product Picture
Figure United States Overactive Bladder Therapeutics Market Size (K Units) by Application (2012-2022)
Figure United States Sales Market Share of Overactive Bladder Therapeutics by Application in 2016
Figure Medical Care Examples
Table Key Downstream Customer in Medical Care
Figure Medical Research Examples
Table Key Downstream Customer in Medical Research
Figure Others Examples
Table Key Downstream Customer in Others
Figure United States Overactive Bladder Therapeutics Market Size (Million USD) by Region (2012-2022)
Figure The West Overactive Bladder Therapeutics Revenue (Million USD) and Growth Rate (2012-2022)
Figure Southwest Overactive Bladder Therapeutics Revenue (Million USD) and Growth Rate (2012-2022)
Figure The Middle Atlantic Overactive Bladder Therapeutics Revenue (Million USD) and Growth Rate (2012-2022)
Figure New England Overactive Bladder Therapeutics Revenue (Million USD) and Growth Rate (2012-2022)
Figure The South of US Overactive Bladder Therapeutics Revenue (Million USD) and Growth Rate (2012-2022)
Figure The Midwest Overactive Bladder Therapeutics Revenue (Million USD) and Growth Rate (2012-2022)
Figure United States Overactive Bladder Therapeutics Sales (K Units) and Growth Rate (2012-2022)
Figure United States Overactive Bladder Therapeutics Revenue (Million USD) and Growth Rate (2012-2022)
Figure United States Overactive Bladder Therapeutics Market Major Players Product Sales Volume (K Units) (2012-2017)
Table United States Overactive Bladder Therapeutics Sales (K Units) of Key Players/Suppliers (2012-2017)
Table United States Overactive Bladder Therapeutics Sales Share by Players/Suppliers (2012-2017)
Figure 2016 United States Overactive Bladder Therapeutics Sales Share by Players/Suppliers
Figure 2017 United States Overactive Bladder Therapeutics Sales Share by Players/Suppliers
Figure United States Overactive Bladder Therapeutics Market Major Players Product Revenue (Million USD) (2012-2017)
Table United States Overactive Bladder Therapeutics Revenue (Million USD) by Players/Suppliers (2012-2017)
Table United States Overactive Bladder Therapeutics Revenue Share by Players/Suppliers (2012-2017)
Figure 2016 United States Overactive Bladder Therapeutics Revenue Share by Players/Suppliers
Figure 2017 United States Overactive Bladder Therapeutics Revenue Share by Players/Suppliers
Table United States Market Overactive Bladder Therapeutics Average Price (USD/Unit) of Key Players/Suppliers (2012-2017)
Figure United States Market Overactive Bladder Therapeutics Average Price (USD/Unit) of Key Players/Suppliers in 2016
Figure United States Overactive Bladder Therapeutics Market Share of Top 3 Players/Suppliers
Figure United States Overactive Bladder Therapeutics Market Share of Top 5 Players/Suppliers
Table United States Players/Suppliers Overactive Bladder Therapeutics Manufacturing Base Distribution and Sales Area
Table United States Players/Suppliers Overactive Bladder Therapeutics Product Category
Table United States Overactive Bladder Therapeutics Sales (K Units) by Region (2012-2017)
Table United States Overactive Bladder Therapeutics Sales Share by Region (2012-2017)
Figure United States Overactive Bladder Therapeutics Sales Share by Region (2012-2017)
Figure United States Overactive Bladder Therapeutics Sales Market Share by Region in 2016
Table United States Overactive Bladder Therapeutics Revenue (Million USD) and Market Share by Region (2012-2017)
Table United States Overactive Bladder Therapeutics Revenue Share by Region (2012-2017)
Figure United States Overactive Bladder Therapeutics Revenue Market Share by Region (2012-2017)
Figure United States Overactive Bladder Therapeutics Revenue Market Share by Region in 2016
Table United States Overactive Bladder Therapeutics Price (USD/Unit) by Region (2012-2017)
Table United States Overactive Bladder Therapeutics Sales (K Units) by Type (2012-2017)
Table United States Overactive Bladder Therapeutics Sales Share by Type (2012-2017)
Figure United States Overactive Bladder Therapeutics Sales Share by Type (2012-2017)
Figure United States Overactive Bladder Therapeutics Sales Market Share by Type in 2016
Table United States Overactive Bladder Therapeutics Revenue (Million USD) and Market Share by Type (2012-2017)
Table United States Overactive Bladder Therapeutics Revenue Share by Type (2012-2017)
Figure Revenue Market Share of Overactive Bladder Therapeutics by Type (2012-2017)
Figure Revenue Market Share of Overactive Bladder Therapeutics by Type in 2016
Table United States Overactive Bladder Therapeutics Price (USD/Unit) by Types (2012-2017)
Figure United States Overactive Bladder Therapeutics Sales Growth Rate by Type (2012-2017)
Table United States Overactive Bladder Therapeutics Sales (K Units) by Application (2012-2017)
Table United States Overactive Bladder Therapeutics Sales Market Share by Application (2012-2017)
Figure United States Overactive Bladder Therapeutics Sales Market Share by Application (2012-2017)
Figure United States Overactive Bladder Therapeutics Sales Market Share by Application in 2016
Table United States Overactive Bladder Therapeutics Sales Growth Rate by Application (2012-2017)
Figure United States Overactive Bladder Therapeutics Sales Growth Rate by Application (2012-2017)
Table Actavis Basic Information List
Table Actavis Overactive Bladder Therapeutics Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Actavis Overactive Bladder Therapeutics Sales Growth Rate (2012-2017)
Figure Actavis Overactive Bladder Therapeutics Sales Market Share in United States (2012-2017)
Figure Actavis Overactive Bladder Therapeutics Revenue Market Share in United States (2012-2017)
Table Allergan Basic Information List
Table Allergan Overactive Bladder Therapeutics Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Allergan Overactive Bladder Therapeutics Sales Growth Rate (2012-2017)
Figure Allergan Overactive Bladder Therapeutics Sales Market Share in United States (2012-2017)
Figure Allergan Overactive Bladder Therapeutics Revenue Market Share in United States (2012-2017)
Table Astellas Pharma Basic Information List
Table Astellas Pharma Overactive Bladder Therapeutics Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Astellas Pharma Overactive Bladder Therapeutics Sales Growth Rate (2012-2017)
Figure Astellas Pharma Overactive Bladder Therapeutics Sales Market Share in United States (2012-2017)
Figure Astellas Pharma Overactive Bladder Therapeutics Revenue Market Share in United States (2012-2017)
Table Pfizer Basic Information List
Table Pfizer Overactive Bladder Therapeutics Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Pfizer Overactive Bladder Therapeutics Sales Growth Rate (2012-2017)
Figure Pfizer Overactive Bladder Therapeutics Sales Market Share in United States (2012-2017)
Figure Pfizer Overactive Bladder Therapeutics Revenue Market Share in United States (2012-2017)
Table Addex Pharmaceuticals Ltd Basic Information List
Table Addex Pharmaceuticals Ltd Overactive Bladder Therapeutics Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Addex Pharmaceuticals Ltd Overactive Bladder Therapeutics Sales Growth Rate (2012-2017)
Figure Addex Pharmaceuticals Ltd Overactive Bladder Therapeutics Sales Market Share in United States (2012-2017)
Figure Addex Pharmaceuticals Ltd Overactive Bladder Therapeutics Revenue Market Share in United States (2012-2017)
Table Bayer Basic Information List
Table Bayer Overactive Bladder Therapeutics Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Bayer Overactive Bladder Therapeutics Sales Growth Rate (2012-2017)
Figure Bayer Overactive Bladder Therapeutics Sales Market Share in United States (2012-2017)
Figure Bayer Overactive Bladder Therapeutics Revenue Market Share in United States (2012-2017)
Table Elbion Basic Information List
Table Elbion Overactive Bladder Therapeutics Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Elbion Overactive Bladder Therapeutics Sales Growth Rate (2012-2017)
Figure Elbion Overactive Bladder Therapeutics Sales Market Share in United States (2012-2017)
Figure Elbion Overactive Bladder Therapeutics Revenue Market Share in United States (2012-2017)
Table Ipsen Basic Information List
Table Ipsen Overactive Bladder Therapeutics Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Ipsen Overactive Bladder Therapeutics Sales Growth Rate (2012-2017)
Figure Ipsen Overactive Bladder Therapeutics Sales Market Share in United States (2012-2017)
Figure Ipsen Overactive Bladder Therapeutics Revenue Market Share in United States (2012-2017)
Table Janssen Basic Information List
Table Janssen Overactive Bladder Therapeutics Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Janssen Overactive Bladder Therapeutics Sales Growth Rate (2012-2017)
Figure Janssen Overactive Bladder Therapeutics Sales Market Share in United States (2012-2017)
Figure Janssen Overactive Bladder Therapeutics Revenue Market Share in United States (2012-2017)
Table Kissei Pharma Basic Information List
Table Kissei Pharma Overactive Bladder Therapeutics Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Kissei Pharma Overactive Bladder Therapeutics Sales Growth Rate (2012-2017)
Figure Kissei Pharma Overactive Bladder Therapeutics Sales Market Share in United States (2012-2017)
Figure Kissei Pharma Overactive Bladder Therapeutics Revenue Market Share in United States (2012-2017)
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Overactive Bladder Therapeutics
Figure Manufacturing Process Analysis of Overactive Bladder Therapeutics
Figure Overactive Bladder Therapeutics Industrial Chain Analysis
Table Raw Materials Sources of Overactive Bladder Therapeutics Major Players/Suppliers in 2016
Table Major Buyers of Overactive Bladder Therapeutics
Table Distributors/Traders List
Figure United States Overactive Bladder Therapeutics Sales Volume (K Units) and Growth Rate Forecast (2017-2022)
Figure United States Overactive Bladder Therapeutics Revenue (Million USD) and Growth Rate Forecast (2017-2022)
Figure United States Overactive Bladder Therapeutics Price (USD/Unit) Trend Forecast (2017-2022)
Table United States Overactive Bladder Therapeutics Sales Volume (K Units) Forecast by Type (2017-2022)
Figure United States Overactive Bladder Therapeutics Sales Volume (K Units) Forecast by Type (2017-2022)
Figure United States Overactive Bladder Therapeutics Sales Volume (K Units) Forecast by Type in 2022
Table United States Overactive Bladder Therapeutics Sales Volume (K Units) Forecast by Application (2017-2022)
Figure United States Overactive Bladder Therapeutics Sales Volume (K Units) Forecast by Application (2017-2022)
Figure United States Overactive Bladder Therapeutics Sales Volume (K Units) Forecast by Application in 2022
Table United States Overactive Bladder Therapeutics Sales Volume (K Units) Forecast by Region (2017-2022)
Table United States Overactive Bladder Therapeutics Sales Volume Share Forecast by Region (2017-2022)
Figure United States Overactive Bladder Therapeutics Sales Volume Share Forecast by Region (2017-2022)
Figure United States Overactive Bladder Therapeutics Sales Volume Share Forecast by Region in 2022
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources